Stock Track | Junshi Biosciences Soars on New Licensing Deal for Nasal Spray Project

Stock Track09-26

Shares of Junshi Biosciences (01877) surged 6.61% on Wednesday, September 26th, to close at a higher level amid positive news regarding a new licensing agreement for one of its pharmaceutical projects.

According to reports, a subsidiary of Junshi Biosciences, Shanghai Junshi Biosciences Co Ltd, entered into a license and cooperation agreement with Nanjing Jsiama Biopharmaceuticals for the development of a nasal spray product, dubbed IAMA-001.

While details of the agreement remain undisclosed, investors seem to have reacted positively to the news, anticipating potential future revenue streams and growth opportunities for the biopharmaceutical company. The licensing deal signals Junshi's commitment to expanding its product pipeline and exploring new therapeutic areas.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1107153024?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-09-26 22:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1107153024","market":"hk","top_or_hot":-1,"title":"Stock Track | Junshi Biosciences Soars on New Licensing Deal for Nasal Spray Project","media":"Stock Track","content":"<p>Shares of Junshi Biosciences (01877) surged 6.61% on Wednesday, September 26th, to close at a higher level amid positive news regarding a new licensing agreement for one of its pharmaceutical projects.</p>\n\n<p>According to reports, a subsidiary of Junshi Biosciences, Shanghai Junshi Biosciences Co Ltd, entered into a license and cooperation agreement with Nanjing Jsiama Biopharmaceuticals for the development of a nasal spray product, dubbed IAMA-001.</p>\n\n<p>While details of the agreement remain undisclosed, investors seem to have reacted positively to the news, anticipating potential future revenue streams and growth opportunities for the biopharmaceutical company. The licensing deal signals Junshi's commitment to expanding its product pipeline and exploring new therapeutic areas.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Junshi Biosciences Soars on New Licensing Deal for Nasal Spray Project</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Junshi Biosciences Soars on New Licensing Deal for Nasal Spray Project\n</h2>\n\n<h4 class=\"meta\">\n\n2024-09-26 22:56 北京时间&nbsp;&nbsp;&nbsp;<strong>Stock Track</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of Junshi Biosciences (01877) surged 6.61% on Wednesday, September 26th, to close at a higher level amid positive news regarding a new licensing agreement for one of its pharmaceutical projects...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01877","symbol_name":"君实生物","start_time":0,"source_url":"","article_id":"1107153024","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1107153024","pubTimestamp":1727362598,"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Junshi Biosciences  surged 6.61% on Wednesday, September 26th, to close at a higher level amid positive news regarding a new licensing agreement for one of its pharmaceutical projects.According to reports, a subsidiary of Junshi Biosciences, Shanghai Junshi Biosciences Co Ltd, entered into a license and cooperation agreement with Nanjing Jsiama Biopharmaceuticals for the development of a nasal spray product, dubbed IAMA-001.While details of the agreement remain undisclosed, investors s","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01877":"君实生物"},"translate_title":"股票赛道君实生物因鼻喷雾剂项目新许可协议而飙升","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01877":1},"content_text":"Shares of Junshi Biosciences (01877) surged 6.61% on Wednesday, September 26th, to close at a higher level amid positive news regarding a new licensing agreement for one of its pharmaceutical projects.\nAccording to reports, a subsidiary of Junshi Biosciences, Shanghai Junshi Biosciences Co Ltd, entered into a license and cooperation agreement with Nanjing Jsiama Biopharmaceuticals for the development of a nasal spray product, dubbed IAMA-001.\nWhile details of the agreement remain undisclosed, investors seem to have reacted positively to the news, anticipating potential future revenue streams and growth opportunities for the biopharmaceutical company. The licensing deal signals Junshi's commitment to expanding its product pipeline and exploring new therapeutic areas.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1107153024"}